Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Sales, net		$ 73,099		$ 387,092
Cost of sales		23,064		174,725
Gross margin		50,035		212,367
Operating Expenses:
Sales and marketing	13,487	336,299	373,087	889,484
Research and development			58,320
Impairment of Goodwill			21,633,882
General and administrative expense	384,417	865,061	3,253,527	2,091,214
Total expenses	397,904	1,201,360	25,318,816	2,980,698
Net loss from operations	(397,904)	(1,151,325)	(25,318,816)	(2,768,331)
Other income (expense):
Other income (expense)	1,110		2,392
Interest expense	(94,985)	(66,573)	(190,046)	(460,114)
Dividend on Series A preferred shares			(231,631)
Expense on inducement of warrant exchange		(480,000)		(650,616)
Expense on issuance of warrant derivative liabilities		(439,428)		(439,428)
Change in fair value of derivative liabilities	504,081	(1,105,844)	1,227,793	(3,735,868)
Total other income (expense)	410,206	(2,091,845)	808,508	(5,286,026)
Net Income (loss) before taxes	12,302	(3,243,170)	(24,510,308)	(8,054,357)
Income tax benefit
Net Income (loss)	12,302	(3,243,170)	(24,510,308)	(8,054,357)
Net loss attributable to the non-controlling interest	(52,283)		(149,183)
Net income (loss) attributable to Common Shareholders of Fuse Science, Inc.	64,585	(3,243,170)	(24,361,125)	(8,054,357)
Unrealized loss on marketable securities	(502)		(713)
Comprehensive income (loss) attributable to Fuse Science, Inc. Common Shareholders	$ 64,083	$ (3,243,170)	$ (24,361,838)	$ (8,054,357)
Net income (loss) per share attributable to Common Shareholders of Fuse Science, Inc., basic and diluted	$ 0.00	$ (0.08)	$ (0.42)	$ (0.21)
Weighted average number of shares outstanding, basic and diluted	78,723,098	40,103,030	58,364,019	38,858,093